Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Published

Journal Article

Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.

Full Text

Duke Authors

Cited Authors

  • Mor, A; Bingham, CO; Barisoni, L; Lydon, E; Belmont, HM

Published Date

  • April 2005

Published In

Volume / Issue

  • 32 / 4

Start / End Page

  • 740 - 743

PubMed ID

  • 15801034

Pubmed Central ID

  • 15801034

International Standard Serial Number (ISSN)

  • 0315-162X

Language

  • eng

Conference Location

  • Canada